ESTRO 2025 - Abstract Book

S3657

Physics - Quality assurance and auditing

ESTRO 2025

Conclusion: This FMEA provides critical insight into FMs needing targeted RTQA in trials where oART is used. Workflow differences impacted centre scores, raising the question of whether standardised procedures are needed for consistency or if end-to-end tests could confirm similar impacts across different workflows. Without a structured QA framework, these FMs pose a risk of cumulative treatment deviations, particularly in patients with significant anatomical variation over the treatment course. By identifying these high risk FMs, we aim to develop RTQA components to provide effective risk mitigation, consistency, and safety for multi-centre, multi-platform clinical trials using oART. This framework will support trials where adaptation is mandated by protocol, and where centres opt to use adaptive techniques where available.

Keywords: Multi-centre FMEA, oART, Clinical Trials QA